GlassScriptPhysician profile
David M Paul
NPI 1851323547
$1,076.63
in general payments reported to CMS, 2019-2025
20 companies · $51.42 in 2025
The $51.42 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $255 · 2021: $64.38 · 2022: $89.14 · 2023: $113 · 2024: $64.81 · 2025: $51.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.16 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $138.55 | 2019-2022 | |
| Pfizer INC. | $127.63 | 2019-2024 | |
| Janssen Biotech, INC. | $120.41 | 2019-2021 | |
| Seagen INC. | $118.35 | 2019-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $95.42 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $90.31 | 2020-2025 | Rylaze |
| Incyte Corporation | $65.13 | 2020-2025 | Pemazyre, Monjuvi, Jakafi |
| Celgene Corporation | $61.84 | 2019-2021 | |
| Genzyme Corporation | $48.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.76 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.19 | 2019-2020 | |
| Lilly USA, LLC | $23.09 | 2019-2020 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Secura Bio, INC. | $17.15 | 2019 | |
| Glaxosmithkline, LLC. | $16.32 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.59 | 2020 | |
| Janssen Scientific Affairs, LLC | $14.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $12.42 | 2019 | |
| Verastem, INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.